China’s medical devices industry saw a rise of 6.67% in overall deal activity during June 2022, when compared with the last 12-month average, led by AstraZeneca Zhongjin Medical Industry Fund, Cambridge Capital Group, SDIC China Merchants Investment Management, Wuyuan Capital and Yunfeng Fund L.P’s $100m venture financing of Axbio, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

A total of 32 deals worth $376.9m were announced in June 2022, compared with the 12-month average of 30 deals.

venture financing was the leading category in the month in terms of volume with 31 deals, which accounted for 96.9% of all deals.

In second place was M&A with one deals accounting for 3.1% of overall deal activity in the China’s technology industry during the month.

In terms of value of deals, venture financing was the leading deal category in China’s medical devices industry with total deals worth $375.63m, followed by M&A and deals totalled $1.29m.

China medical devices industry deals in June 2022: Top deals

The top five medical devices industry deals accounted for 63.6% of the overall value during June 2022.

The combined value of the top five medical devices deals stood at $239.88m, against the overall value of $376.9m recorded for the month.

The top five medical devices industry deals of June 2022 tracked by GlobalData were:

1) AstraZeneca Zhongjin Medical Industry Fund,Cambridge Capital Group,SDIC China Merchants Investment Management,Wuyuan Capital and Yunfeng Fund L.P $100m venture financing deal with Axbio

2) The $50m venture financing of NuProbe Global by BioTrack Capital,CICC Fund Management,CR-CP Life Science Fund,Deguan Capital,Haoreng Capital,Pappas Capital,Sequoia Capital China,Shanghai Pan Lin Asset Management and Yonghua Capital

3) Brilliance Meijing,Fengshi Capital,Galaxy Yuanhui Investment,Gandao Investment Holding Group,Junci Investment,Qiaodao Investment Fund Management (Beijing),Shengxiang Biotechnology and Wuxi Guojing Investment Management $44.98m venture financing deal with Shanghai Singlera Genomics Technologies

4) The $29.93m venture financing of Guangzhou Jiajian Medical Testing by Besen Medical Fund,CICC Qide Fund,Jiuzhoutong Venture Capital and Yueke Finance

5) Founder Securities and Tao Capital Partners $14.98m venture financing deal with Danyang Huichuang Medical Equipment